Abstract: Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: A process for making a cyclic compounds such as cyclic acetal or cyclic ketones by feeding aldehyde or ketone compounds and polyhydroxyl compounds to a reaction zone at a molar ratio of polyhydroxyl compounds to aldehyde or ketone compounds of at least 3:1, reacting these compounds in the presence of a solid acid such as an acidic ion exchange resin, to generate a liquid reaction mixture without separating water from the reaction mixture as it is being formed in the reaction mixture, withdrawing the liquid reaction mixture from the reaction zone as a liquid product stream, and feeding the liquid reaction product stream to a distillation column to separate cyclic acetal compounds from unreacted polyhydroxyl compounds, and optionally recycling back the unreacted polyhydroxyl compounds to the reaction zone. The process produces cyclic acetal compounds in yields of at least 90% with long catalyst life. The process is also suitable to make cyclic ketals from ketone compounds.

Abstract: The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and/or formula (II) as herein defined.

Abstract: The present disclosure provides methods for purifying p-dioxanone. In embodiments, crude p-dioxanone may be contacted with at least one isocyanate-functionalized scavenger. The at least one isocyanate-functionalized scavenger may react with hydroxyl compounds present with the crude p-dioxanone to form reaction products, in embodiments polyurethanes and/or polyureas, which may then be removed. The p-dioxanone thus obtained is of greater purity than the starting crude p-dioxanone.

Abstract: The present invention relates to novel acylmethylene-1,3-dioxolanes and acylmethylene-1,4-dioxanes of the general formula (I) in which R1, R2, R3 and n have the meanings given in the description, and also a novel process for their preparation. Acylmethylene-1,3-dioxolanes and acylmethylene-1,4-dioxanes are important intermediates for the preparation of pyrazoles and anthranilamides, which can be used as insecticides.

Abstract: The present disclosure provides methods for purifying p-dioxanone. In embodiments, crude p-dioxanone may be contacted with at least one isocyanate-functionalized scavenger. The at least one isocyanate-functionalized scavenger may react with hydroxyl compounds present with the crude p-dioxanone to form reaction products, in embodiments polyurethanes and/or polyureas, which may then be removed. The p-dioxanone thus obtained is of greater purity than the starting crude p-dioxanone.

Abstract: The invention relates to tricyclic aromatics of the general formula I in which A1, A2, A3, A4, Q1-Q2, R1, R2, X1, X2, X3, Z1, Z2, Z3, Z4, q, r, s, t and u have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing same.

Abstract: The anthranilic acid derivative or the salt thereof represented by the general formula wherein R1 and R2 are hydrogen atom, or the like; R3 is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R4 is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X1 is an alkylene or alkenylene group which may be substituted or a bond; X2 is the general formula -X3-X4- or -X4-X3-, wherein X3 is a sulfur atom, an imino group or a bond, or the like; X4 means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP-13 production inhibitory effect.

Abstract: Novel PDF inhibitors and novel methods for their use are provided.

Abstract: The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.

Abstract: A novel method for the preparation of a compound of formula (I) from an N—protected-D-mannosamine. A compound of formula (I) is a useful intermediate for the preparation of kiftnensine, a potent and selective mannosidase inhibitor. The method includes protecting the hydroxyl group at the C-6 position of an N—protected-D-mannosamine, to give a 6—O—protected—N—protected-D-mannosamine; reducing the C-1 anomeric carbon atom of the 6—O—protected—N—protected-D-mannosamine to give a 6—O—protected—N—protected-D-mannitol; protecting the four hydroxyl groups of the 6—O—protected—N—protected-D-mannitol; and removing the nitrogen atom protecting group and optionally removing the C-6 oxygen atom protecting group to give the compound of formula (I): where R1 and R2 are each independently protecting groups which, together with the oxygen atoms to which they are attached, form a 5-, 6-, 7- or 8-membered ring; and R3 is hydrogen or a protecting group.

Abstract: An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.

Abstract: Primary intermediates for hair coloring compositions for oxidative dyeing of hair are compounds of the formula (1): wherein R is hydrogen, hydroxy, nitro, amino, halogen, C1 to C5 alkyl or haloalkyl, C1 to C5 alkoxy or cyclic alkoxy, C1 to C5 hydroxyalkyl and C1 to C5 hydroxyalkoxy; Ar is an aromatic group, preferably an aromatic group selected from a furanyl, thienyl, pyridinyl, phenyl, 2,3-dihydro-benzo[1,4]dioxin-5 or -6-yl or benzo[1,3]dioxol-4 or -5-yl group; and y=1 to 3.

Abstract: Compounds of the formula I in which X, Y, Z, R1, R2, R3, R4, R5, R7, R8, R11, m and n have the meanings stated in claim 1, and their physiologically acceptable salts can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, for pathological processes maintained or propagated by angiogenesis, and in tumour therapy.

Abstract: Couplers for hair coloring compositions for oxidative dyeing of hair are compounds of the formula (1): wherein R is selected from the group consisting of C1 to C2 alkyl and hydroxyethyl; R1 is selected from the group consisting of a hydrogen, hydroxy, nitro, halogen, C1 to C5 alkyl or haloalkyl, C1 to C5 alkoxy or cycloalkoxy, C1 to C5 hydroxyalkyl and C1 to C5 hydroxyalkoxy; Ar is an aromatic group, preferably an aromatic group selected from the group consisting of a furyl, thienyl, pyridyl, phenyl, 2,3-dihydro-benzo[1,4]dioxin-5 or -6-yl or benzo[1,3]dioxol-4 or -5-yl group; and y=1 to 3.

Abstract: Provided are liquid crystalline compounds having excellent physical properties and being excellent in miscibility with other liquid crystal materials; liquid crystal compositions comprising the crystalline compound; and liquid crystal display device fabricated by using the liquid crystal composition; the liquid crystalline compounds being specific chlorobenzene derivatives expressed by the general formula (1) Ra—A1—Z1—A2&Parenopenst;Z2—A3&Parenclosest;m&Parenopenst;Z3—A4&Parenclosest;nRb  (1) wherein Ra, Rb, A1 to A4, Z1 to Z3, m, and n are herein defined.

Abstract: The invention relates to novel cyclic imines of the formula (I) in which Ar1 and Ar2 each represent substituted phenyl and n represents 1, to a process for their preparation and to their use as pesticides.

Abstract: Unsaturated cyclic ethers of the formula I ##STR1## whereZ is --(CHR.sup.4).sub.q -- or --(CHR.sup.4).sub.q --O--,q is 0, 1, 2 or 3 andR.sup.1,R.sup.2,R.sup.3,R.sup.4 are hydrogen or C.sub.1 -C.sub.4 -alkylare prepared by reacting diols of the formula II ##STR2## where Z, R.sup.1, R.sup.2 and R.sup.3 are as defined above, in the liquid phase at from 150 to 300.degree. C. in the presence of a cobalt-containing supported catalyst which has not been activated by reduction before use and comprises cobalt and a noble metal selected from the group consisting of platinum, palladium, rhodium, iridium, ruthenium, osmium, rhenium or a mixture thereof applied by sol impregnation on an inert support, wherein the supported catalyst is doped with sulfur. Sulfur-doped supported catalysts comprising cobalt and noble metals are also provided.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is alkyl; R.sup.2a, R.sup.2b, R.sup.2c and R.sup.2d are the same or different and each is hydrogen, optionally substituted alkyl or various other organic groups; R.sup.3 is alkyl; R.sup.4 is a group of formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX): ##STR2## wherein: A.sup.1 is a single bond, alkylene or alkenylene; A.sup.2 is or alkenylene; A.sup.3 is a single bond, alkyleneor alkenylene; R.sup.5a and R.sup.5b are the same or different and each is hydrogen, alkyl or various other groups; R.sup.6 is alkyl or phenyl; R.sup.7 is hydrogen or alkyl; R.sup.8 is alkyl or various other groups; and n is 0 and pharmaceutically acceptable salts thereof have valuable inhibitory activity against acyl-CoA: cholesterol acyl transferase.

Abstract: A process for the catalytic addition of nucleophilic agents to alkynes or allenes to form alkenes substituted by the nucleophile which may further react with the nucleophile and/or isomerize comprises using a catalyst comprising a wholly or partly ionized complex of univalent gold.

Abstract: Substituted amino compounds of general formula (I) ##STR1## are described, as are a method of preparing them and their use as drugs, especially as analgesics.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is alkyl; R.sup.2a, R.sup.2b, R.sup.2c and R.sup.2d are the same or different and each is hydrogen, optionally substituted alkyl, --(C.dbd.O)--B.sup.1 (wherein B.sup.1 is hydrogen or alkyl), nitro, --NR.sup.c R.sup.d (wherein R.sup.c is hydrogen or alkyl and Rd is alkyl), hydroxy, protected hydroxy group, alkoxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl or halogen;R.sup.3 is alkyl; R.sup.4 is a group of the formula (II) ##STR2## wherein A.sup.1 is a single bond, alkylene or alkenylene; R.sup.5a and R.sup.5b are the same or different and each is hydrogen, alkyl or --A.sup.4 R.sup.5.sub.c wherein A is a single bond, alkylene or alkenylene and R.sup.5.sub.c is alkoxy; and n is 0, and pharmaceutically acceptable salts thereof. Such compounds have valuable inhibitory activity against acyl-CoA (cholesterol acyl transferase).

Abstract: Nonlinear optical compounds which contain a heteroaromatic ring and may further comprise a tricyanovinyl group attached to the heteroaromatic ring.

Abstract: Liquid crystalline alkenyl cyclohexane compounds of formula (I) having a nematic phase over a broad temperature range, a higher elastic constant ratio K.sub.33 /K.sub.11 and a lower viscosity, liquid crystal compositions comprising the above compounds and liquid crystal display elements using the liquid crystal compositions. ##STR1## wherein R.sub.1 is an alkyl group of 1-15 carbons, an alkenyl group of 2-15 carbons or an alkyl or alkenyl group in which at least one of non-adjacent methylene groups (--CH.sub.2 --) is replaced by --O--, --S--, --C.tbd.C-- or --COO--; R.sub.2 is a hydrogen atom or an alkyl group of 1-10 carbons; m is 0-5; when m is 2 or more, any one methylene group in --(CH.sub.2).sub.m -- may be replaced by --O--; and the rings A.sub.1, A.sub.2 and A.sub.3 are independently a 1,4-cyclohexylene, a cyclohexene-1,4-diyl or a 6-membered ring group, one or two --CH.sub.2 -- groups in said rings optionally replaced by --O-- or --S--.

Abstract: A process for the preparation of unsaturated cyclic ethers of the general formula I ##STR1## in which Z denotes --(CHR.sup.4).sub.q or --(CHR.sup.4).sub.q --O--q is 0, 1, 2 or 3 andR.sup.1, R.sup.2, R.sup.3, and R.sup.4 denote hydrogen or C.sub.1 -C.sub.4 alkyl from diols of the general formula II ##STR2## in which, R.sup.1, R.sup.2, and R.sup.3 have the aforementioned meanings, in the presence of a cobalt-containing supported catalyst, wherein the cobalt-containing supported catalyst used contains cobalt and a noble metal--selected from the group consisting of platinum, palladium, rhodium, iridium, ruthenium, osmium, rhenium, or mixtures thereof--in an atomic ratio of from 0.5:1 to 70000:1 on an inert support and optionally basic alkali metal and alkaline earth metal salts, scandium, vanadium, chromium, manganese, iron, nickel, copper, zinc, germanium, tin, lead, antimony, bismuth, or mixtures thereof and the reaction is carried out in the liquid phase at temperatures ranging from 150.degree. to 300.degree.

Abstract: A process for the preparation of acetals by reacting one or more ethylenically unsaturated compounds with carbon monoxide, hydrogen and a liquid or dissolved organic nucleophilic compound containing at least two vicinal hydroxy groups in the presence of a catalyst system comprising:a) a source of plantinum;b) a source of anions; andc) a bidentate ligand of the formulaR.sup.1 R.sup.2 M.sup.1 RM.sup.2 R.sup.3 R.sup.4 (I)wherein M.sup.1 and M.sup.2 independently represent a phosphorus, arsenic or antimony atom, R represents a bivalent organic bridging group containing from 1 to 4 atoms in the bridge, R.sup.1 and R.sup.2 together represent a bivalent substituted or non-substituted cyclic group whereby the two free valencies are linked to M.sup.1 and R.sup.3 and R.sup.4 independently represent a substituted or non-substituted hydrocarbyl group, or together represent a bivalent substituted or non-substituted cyclic group whereby the two free valencies are linked to M.sup.2.

Abstract: A production stimulator of nerve growth factor contains a new cyathane derivative of the form ##STR1## where R is either CHO or CH.sub.2 OH.

Abstract: A method and apparatus are disclosed for decontaminating a liquid surfactant of a dioxane having a vapor pressure which is higher than the surfactant. A contaminated liquid surfactant is directed through an inclined conduit. A gas is directed into the inclined conduit, whereby the gas contacts the surfactant and transports the dioxane contaminant, which has volatilized in the inclined conduit, out of the inclined conduit, thereby decontaminating the surfactant. The liquid surfactant is discharged from the inclined conduit.

Abstract: The invention relates to 9-substituted bicyclo[3.3.0]octane derivatives of formula I, ##STR1## and their salts with physiologically compatible bases, as well as the .alpha.-, .beta.- or .gamma.-cyclodextrin clathrates, as well as the compounds of formula I encapsulated with liposomes, process for their production and their pharmaceutical use.

Abstract: New cyathane derivatives shown by Formula (1) or (2) given below have the effect of stimulating production of nerve growth factors and antimicrobial effects: ##STR1## where R is either CHO or CH.sub.2 OH.

Abstract: Axial anomeric sulfoxides generated via thiophenol Ferrier rearrangement of glucal and galactal derivatives are used to synthesize glycals of the gulal and allal series. An application of the method led to the synthesis of the esperamicin thiosugar.

Abstract: This invention provides certain sulfonimidamide compounds, formulations and method of use of these compounds in treating susceptible neoplasms.

Abstract: Axial anomeric sulfoxides generated via thiophenol Ferrier rearrangement of glucal and galactal derivatives are used to synthesize glycals of the gulal and allal series. An application of the method led to the synthesis of the esperamicin thiosugar.

Abstract: Novel labdanes, intermediates and processes for the preparation thereof, and methods for reducing intraocular pressure utilizing compounds or compositions thereof are disclosed.

Abstract: Compounds of the general formula I ##STR1## in which R.sup.1 represents a hydrogen atom or an alkyl group of the formula CH.sub.3 (CH.sub.2).sub.n --where n=0 to 5,R.sup.2 represents a hydrogen atom when X is a carbamoyl group, an alkyl group having 1 to 6 carbon atoms, a group, bonded in an ether-like fashion, of the formula R.sup.3 --O--CH.sub.2 --(CHR.sup.4).sub.m --CH.sub.2 -- in whichR.sup.3 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms,R.sup.4 is a hydroxyl group or an alkyloxy group having 1 to 3 carbon atoms, and m is 0 to 2, represents a group, bonded in an ether-like fashion, of the formula H--(CH.sub.2).sub.a --(O--(CH.sub.2).sub.b).sub.c -- where a=0 to 4, b=1 to 4 and c=1 to 7, orR.sup.2 represents a radical, bonded in a O-glycoside fashion of the formula ##STR2## in whichR.sup.5, R.sup.6 and R.sup.7, independently of one another, are a hydrogen atom or a hydroxyl group, andR.sup.

Abstract: The invention relates to the dioxane adducts of armoatic meta-or para-hydroxycarboxylic acids, which consist, per mole, of 1 mole of 1,4-dioxane and about 2 moles of hydroxycarboxylic acid. The invention further relates to a process for the preparation of these adducts, which comprises dissolving the hydroxycarboxylic acids in dioxane or a mixture of the latter with water or with an organic solvent and then allowing the adducts to crystallize.

Abstract: Methods and compositions for enhancing magnetic resonance imaging in at least a portion of a warm-blooded animal.

Abstract: A compound having the structural formula ##STR1## where R is at least one of hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, cyano, phenyl, phenoxy, benzyl or COOR.sup.1 ; and R.sup.1 is C.sub.1 -C.sub.4 alkyl is disclosed. A composition comprising a growth regulant effective amount of the compound and a carrier therefor is also set forth. In addition, a process for regulating plant growth comprising applying a plant growth regulant effective amount of the compound to the locus of the plant whose growth is to be regulated is taught.

Abstract: The invention relates to the dioxane adduct of 2-hydroxynaphthalene-6-carboxylic acid which adduct comprises 1 mol of 1,4-dioxane and about 2 mol of 2-hydroxynaphthalene-6-carboxylic acid per mol. The invention further relates to a process for the preparation of this adduct, wherein the 2-hydroxynaphthalene-6-carboyxlic acid is dissolved in dioxane or a mixture thereof with water or with an organic solvent and then allowed to crystallize.

Abstract: Cyclic 6-membered to 8-membered 1,2-vinylenedioxy compounds of the general formula I ##STR1## where A is ##STR2## R.sup.1 to R.sup.7 independently of one another are each hydrogen, C.sub.1 -C.sub.8 -alkyl, C.sub.2 -C.sub.16 -alkoxyalkyl, C.sub.2 -C.sub.8 -alkenyl, C.sub.2 -C.sub.8 -alkynyl, C.sub.5 -C.sub.8 -cycloalkyl, aryl, C.sub.7 -C.sub.10 -alkylphenyl, C.sub.7 -C.sub.10 -phenalkyl, C.sub.8 -C.sub.10 -phenalkenyl or a heterocyclic structure, or R.sup.2 and R.sup.3, R.sup.2 and R.sup.4, R.sup.3 and R.sup.4, R.sup.2 and R.sup.6, R.sup.3 and R.sup.6, R.sup.4 and R.sup.5 or R.sup.6 and R.sup.7 together form a cycloaliphatic or heterocyclic ring, and R.sup.1 to R.sup.7 may furthermore carry substituents which are inert under the reaction conditions, and n is 0 or 1, are prepared by a process in which a cyclic 2-oxymethyl-1,3-dioxa compound or one of its derivatives of the general formula II ##STR3## where R.sup.1 to R.sup.7, A and n have the abovementioned meanings, and R.sup.8 is hydrogen or C.sub.1 -C.sub.

Abstract: Ether-substituted isonitriles, Tc99m complexes thereof, and processes for myocardial tissue radioimaging using the Tc99m complexes.

Abstract: It has been surprisingly discovered in accordance with the present invention that glycol formates and their alkyl ether derivatives can be substantially selectively converted to monocarboxylic acids by bringing a glycol formate or an alkyl ether derivative thereof into contact with a bed of activated carbon in the presence of carbon monoxide and a halide promoted group VIII soluble transition metal catalyst optionally in the presence of a solvent.

Abstract: An improved method for dehydration and concentration of an aqueous solution containing an organic compound is disclosed. The solution is evaporated to produce a gaseous mixture comprising an organic compound vapor and a water vapor. The water vapor is selectively removed from the gaseous mixture by permeation through an aromatic polyimide gas separation membrane while the gaseous mixture being kept in contact with a surface on one side of the gas separation membrane at a temperature of 70.degree. C. or higher to obtain a gaseous mixture comprising the organic compound vapor and a reduced amount of a water vapor.

Abstract: Dioxane cannot be completely removed from dioxane and formic acid mixtures by distillation because of the presence of the maximum azeotrope. Dioxane can be readily removed from dioxane - formic acid mixtures by extractive distillation in which the extractive agent is dimethylformamide, dimethylacetamide or these with certain high boiling organic compounds.

Abstract: The invention relates to the dioxane adduct of 2-hydroxynaphthalene-6-carboxylic acid which adduct comprises 1 mol of 1,4-dioxane and about 2 mol of 2-hydroxynaphthalene-6-carboxylic acid per mol. The invention further relates to a process for the preparation of this adduct, wherein the 2-hydroxynaphthalene-6-carboxylic acid is dissolved in dioxane or a mixture thereof with water or with an organic solvent and then allowed to crystallize.

Abstract: Compounds suitable for being used as lubricants, having general formula:(I) RO--(C.sub.3 F.sub.6 O).sub.m --(CFXO).sub.n --CFX--L, or(II) R"CFXO--(C.sub.3 F.sub.6 O).sub.x (CFXO).sub.y --(C.sub.2 F.sub.4 O).sub.z --CFX--L, whereR=--CF.sub.3, --C.sub.2 F.sub.5, --C.sub.3 F.sub.7X=F, --CF.sub.3R"=F, --CF.sub.3, --C.sub.2 F.sub.5m=an integer from 3 to 100n=a finite integer, or =zero, wherefore m+n ranges from 3 to 100, provided that, if n is finite, m/n ranges from 5 to 20 and R is preferably =CF.sub.3, if n=zero, R is preferably --C.sub.2 F.sub.5 or --C.sub.3 F.sub.7x=a finite integer, or =zeroy, z=finite integers, such that x+y+z ranges from 5 to 200, while (x+z)/y ranges from 5 to 0.5, provided that when x=zero, z/y ranges from 1 to 0.5 and y+z ranges from 5 to 200 n while X is preferably F, and R"=LL=group Y-Z, where:Y=--CH.sub.2 O--, --CH.sub.2 --OCH.sub.2, --CF.sub.2, --CF.sub.

Abstract: A process is disclosed for preparing a cyclic ether which comprises cyclodehydrating a polyhydroxy compound of the general formulaHOR.sup.1 HC--R.sup.2 --CHR.sup.3 OHin which R.sup.1 and R.sup.3, each of which is the same or different, is hydrogen or a lower aliphatic, cycloaliphatic or aryl group and R.sup.2 is a divalent aliphatic group of 1 to 10 carbon atoms containing 0, 1 or 2 etheric oxygen atoms or 0, 1 or 2 secondary or tertiary amine nitrogen atoms and 0, 1 or more lower aliphatic, cycloaliphatic and/or aryl groups containing 0 or 1 hydroxyl groups at elevated temperatures in the presence of a catalytically effective amount of a Group VIII metal catalyst or a Group VIII metal-containing material to provide a cyclic ether of the general formula ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 are as defined above.

Abstract: Tetrahydro(thio)pyran-2,4-dione derivatives of the formula ##STR1## where R.sup.1 is hydrogen, a cation, alkylcarbonyl, C.sub.2 -C.sub.10 -alkenylcarbonyl, or benzoyl which is unsubstituted or substituted by alkyl, R.sup.2 is alkyl, R.sup.3 is a non-aromatic, unsubstituted or alkyl-substituted heterocyclic compound of 5 to 7 ring members and having at most one double bond in the heterocyclic ring, X is oxygen or sulfur, and Z is oxygen or the radical NO--R.sup.4, R.sup.4 denoting alkyl, alkenyl, alkynyl, haloalkyl, hal oalkenyl, alkoxyalkyl or the radical CH.sub.2 --R.sup.5, where R.sup.5 is a he terocyclic compound of 5 ring members and containing from 1 to 3 hetero-atoms and from 0 to 2 double bonds and bearing either no substituents or one or two substituents selected from the group consisting of alkyl, alkoxy, halogen, trifluoromethyl, alkoxymethyl, alkylthiomethyl and vinyl, or R.sup.

Abstract: Dioxane cannot be completely removed from dioxane and formic acid mixtures by distillation because of the presence of the maximum azeotrope. Dioxane can be readily removed from dioxane - formic acid mixtures by extractive distillation in which the extractive agent is dimethylsulfoxide, either alone or admixed with certain high boiling organic compounds. Examples of effective agents are dimethylsulfoxide; DMSO and octanoic acid; DMSO, neodecanoic acid and methyl salicylate.

Abstract: High molecular weight polyethylene glycol monoethers are cleaved to prepare lower oligomeric reaction products by contacting a mixture of the high molecular weight polyethylene glycol monoether and water with a hydrolytic cleavage catalyst such as alumina at elevated temperatures.